NATCO Pharma Balance Sheet Health
Financial Health criteria checks 6/6
NATCO Pharma has a total shareholder equity of ₹52.9B and total debt of ₹2.5B, which brings its debt-to-equity ratio to 4.7%. Its total assets and total liabilities are ₹62.5B and ₹9.6B respectively. NATCO Pharma's EBIT is ₹14.6B making its interest coverage ratio -35.9. It has cash and short-term investments of ₹12.2B.
Key information
4.7%
Debt to equity ratio
₹2.48b
Debt
| Interest coverage ratio | -35.9x |
| Cash | ₹12.16b |
| Equity | ₹52.94b |
| Total liabilities | ₹9.61b |
| Total assets | ₹62.54b |
Recent financial health updates
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden
Nov 30Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 24These 4 Measures Indicate That NATCO Pharma (NSE:NATCOPHARM) Is Using Debt Reasonably Well
Mar 22Recent updates
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 22Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
Feb 16Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden
Nov 30Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 24These 4 Measures Indicate That NATCO Pharma (NSE:NATCOPHARM) Is Using Debt Reasonably Well
Mar 22Should NATCO Pharma Limited (NSE:NATCOPHARM) Be Part Of Your Dividend Portfolio?
Mar 04Financial Position Analysis
Short Term Liabilities: NATCOPHARM's short term assets (₹33.5B) exceed its short term liabilities (₹8.8B).
Long Term Liabilities: NATCOPHARM's short term assets (₹33.5B) exceed its long term liabilities (₹822.0M).
Debt to Equity History and Analysis
Debt Level: NATCOPHARM has more cash than its total debt.
Reducing Debt: NATCOPHARM's debt to equity ratio has reduced from 6.5% to 4.7% over the past 5 years.
Debt Coverage: NATCOPHARM's debt is well covered by operating cash flow (302.1%).
Interest Coverage: NATCOPHARM earns more interest than it pays, so coverage of interest payments is not a concern.